APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma

Gut

Volumn 64, Issue 10, 2015, Pages 1506-1516

  Liu, David S H ^a,b   Read, Matthew ^a,b   Cullinane, Carleen ^a,b   Azar, Walid J ^a   Fennell, Christina M ^a   Montgomery, Karen G ^a   Haupt, Sue ^a   Haupt, Ygal ^a   Wiman, Klas G ^c   Duong, Cuong P ^a   Clemons, Nicholas J ^a,b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APR 246; CISPLATIN; EPIRUBICIN; FLUOROURACIL; MUTANT PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; 2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; QUINUCLIDINE DERIVATIVE; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE ASSAY; CHEMOSENSITIVITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CRISPR CAS SYSTEM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; IN VITRO STUDY; MOUSE; NONHUMAN; NULL CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASMS, EXPERIMENTAL; QUINUCLIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941367626     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309770     Document Type: Article

References (37)

1. Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012;23:3155-62.
2. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92.
3. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45:478-86.
4. Weaver JM, Ross-Innes CS, Shannon N, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-43.
5. Yamasaki M, Miyata H, Fujiwara Y, et al. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 2010;17:634-42.
6. Madani K, Zhao R, Lim HJ, et al. Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg 2010;37:1427-32.
7. Bassett EA, Wang W, Rastinejad F, et al. Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 2008;14:6376-86.
8. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012;30:3633-9.
9. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009;15:376-88.
10. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002;8:282-8.
11. Saha MN, Jiang H, Yang Y, et al. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther 2013;12:2331-41.
12. Tessoulin B, Descamps G, Moreau P, et al. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood 2014;124:1626-36.
13. Peng X, Zhang MQ, Conserva F, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis 2013;4:e881.
14. Rokaeus N, Klein G, Wiman KG, et al. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Oncogene 2007;26:982-92.
15. Rokaeus N, Shen J, Eckhardt I, et al. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 2010;29:6442-51.
16. Clemons NJ, Do H, Fennell C, et al. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci 2014;59:78-88.
17. Morales CP, Gandia KG, Ramirez RD, et al. Characterisation of telomerase immortalised normal human oesophageal squamous cells. Gut 2003;52:327-33.
18. Page B, Page M, Noel C. A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol 1993;3:473-6.
19. Sheppard KE, Cullinane C, Hannan KM, et al. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer 2013;49:3936-44.
20. Franken NA, Rodermond HM, Stap J, et al. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
21. Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
22. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006;1:1458-61.
23. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85.
24. Aubrey B, Kelly G, Kueh A, et al. An inducible lentiviral guide RNA platform enables the identification of tumor essential genes and novel tumor promoting mutations in vivo. Cell Reports 2015;10:1422-32.
25. Ran FA, Hsu PD, Wright J, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 2013;8:2281-308.
26. Chou TC Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
27. Read M, Liu D, Duong CP, et al. Intramuscular transplantation improves engraftment rates for esophageal patient-derived tumor xenografts. Ann Surg Oncol 2015. Published Online First: 18 Feb 2015. doi:10.1245/s10434-015-4425-3
28. Bykov VJ, Issaeva N, Selivanova G, et al. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 2002;23:2011-18.
29. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
30. Hadji A, Clybouw C, Auffredou MT, et al. Caspase-3 triggers a TPCK-sensitive protease pathway leading to degradation of the BH3-only protein puma. Apoptosis 2010;15:1529-39.
31. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999;18:1131-8.
32. Shchors K, Persson AI, Rostker F, et al. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc Natl Acad Sci USA 2013;110:e1480-9.
33. Aryee DN, Niedan S, Ban J, et al. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. Br J Cancer 2013;109:2696-704.
34. Bykov VJ, Zache N, Stridh H, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005;24:3484-91.
35. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005;68:261-71.
36. Spechler SJ Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013;310:627-36.
37. Anders M, Bahr C, El-Masry MA, et al. Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection. Gut 2014;63:1535-43.